There are dozens of reasons corporate executives sell shares.

They may need money to pay taxes, buy a house, settle a divorce, diversify their wealth, or fund a new boat they will use three times before deciding they hate boating.

There is usually only one reason they reach into their own pockets and buy shares on the open market.

They believe the stock is worth more than the price they are paying.

That does not mean every insider purchase will produce an immediate profit. Corporate executives can be early, overly optimistic, or simply wrong.

However, when a stock has been cut in half and several members of the C-suite begin buying meaningful amounts of stock with their own money, I pay attention.

These people are not working from an analyst presentation or an earnings model assembled in a Manhattan office tower.

They see the orders coming in.

They know which customers are paying on time.

They know whether margins are stabilizing, whether the sales pipeline is real, and whether the problems frightening Wall Street can be fixed.

Academic research supports what common sense tells us.

Insider purchases have historically been more informative than insider sales, particularly among smaller companies and stocks with low valuations and weak recent price performance. Research has also found that purchases by several insiders are more powerful than isolated transactions.

That makes the current buying at Boston Scientific, Cardinal Infrastructure Group, GBank Financial Holdings, and Amrize worth investigating.

All four stocks are trading far below their 52-week highs.

More importantly, the people running these businesses are not hiding under their desks.

They are buying.

Boston Scientific (BSX)

Boston Scientific is the standout entry on our list.

Shares have been cut nearly in half, falling from a 52-week high of $109.50 to roughly $50.

Wall Street has gone from enthusiastic to deeply skeptical as investors digest slower growth expectations, acquisition concerns, and the effects of a recent cybersecurity disruption.

Chairman, President and CEO Michael Mahoney responded to the earlier decline by making an enormous open-market purchase.

On Aug. 3, he bought 186,240 shares at an average price of approximately $48.33.

He committed about $9 million of his own money to the stock.

This was not a token purchase designed to create a favorable headline.

It was a serious investment.

The decline has also occurred while the underlying business continues to grow.

Boston Scientific reported second-quarter sales of $5.44 billion, an increase of 7.5% from the prior year. Organic sales increased 7%.

The company remains a major participant in cardiology, electrophysiology, endoscopy, urology, and other attractive medical markets.

Its products are used in procedures that patients cannot simply postpone forever.

Boston Scientific faces real challenges.

Management must integrate acquisitions, restore investor confidence, and deal with the operational effects of the cyberattack.

Yet the market has already delivered a punishment generally associated with a business in secular decline.

That description does not fit a company that is still growing sales, producing billions of dollars in annual free cash flow, and occupying important positions in some of the fastest-growing medical device categories.

Mahoney knows more about the company’s products, competitive position, and acquisition pipeline than anyone on Wall Street.

His $9 million purchase does not guarantee a recovery.

It tells us that the man in charge sees a very different future than the stock price currently implies.

Cardinal Infrastructure Group (CDNL)

Cardinal Infrastructure Group provides civil infrastructure and site-development services across the Southeast.

Its crews perform grading, site clearing, water and sewer installation, stormwater work, paving, and other services required before residential, commercial, and industrial construction can move forward.

Cardinal came public in late 2025 and quickly became one of those new issues investors could not get enough of.

The shares eventually reached $96.40.

They currently trade near $36, leaving the stock more than 60% below its high.

The collapse in price suggests Cardinal’s growth story has been destroyed.

The operating results tell a more complicated story.

Second-quarter revenue increased 114% to $226.9 million, including approximately 64% organic growth.

Adjusted EBITDA increased 43% to $28.1 million.

Margins declined as the company relied more heavily on subcontractors and equipment rentals while investing in its corporate infrastructure.

Wall Street saw the margin pressure and ran for the exits.

Management saw the decline and opened its checkbook.

CEO Jeremy Spivey purchased 83,350 shares for approximately $3.2 million.

Chief Operating Officer Benjamin Wood bought 25,700 shares for just over $1 million.

CFO Michael Rowe purchased 7,000 shares for approximately $256,000.

Directors added millions of dollars in additional buying.

This is precisely the pattern I want to see after a stock-price collapse.

The CEO, CFO, and chief operating officer are all participating.

These are the executives closest to operating performance, cash flow, expenses, and the project pipeline.

Cardinal must prove that it can convert rapid revenue growth into durable margins and free cash flow.

That is the issue the market is worried about, and it is a legitimate concern.

The insiders apparently believe the current discount reflects far more trouble than the company is likely to experience.

When the CEO puts up $3.2 million and the chief operating officer adds another $1 million after a 60% decline, I am willing to take a closer look.

GBank Financial Holdings (GBFH)

GBank Financial Holdings is a small Las Vegas bank holding company with a market capitalization of approximately $290 million.

Through GBank, it provides commercial banking, Small Business Administration lending, commercial real estate financing, equipment loans, and other financial services.

The stock is down more than 50% this year, falling from a high of $42.23 to approximately $20, and sits near the bottom of its annual range.

CEO Jeffrey Newgard purchased 32,263 shares on Aug. 3 and Aug. 4 at prices of approximately $21.54 to $21.75.

His purchases totaled close to $700,000.

He was not alone.

Over a recent 90-day period, five company insiders reportedly made eight open-market purchases with a combined value of approximately $1.74 million.

That is a substantial commitment for a company of this size.

The operating results also suggest the stock price may be painting an excessively dark picture.

Second-quarter net revenue increased 23.5% from the prior year to $22 million.

Net income was approximately $5.5 million, while loans reached $1.05 billion and deposits totaled $1.21 billion.

GBFH is still a small bank and should be treated accordingly.

Credit quality, funding costs, loan concentrations, and liquidity must be watched closely.

Smaller banks can also be thinly traded, making position sizing especially important.

The combination of improving revenue, a depressed share price, and broad insider participation is nevertheless encouraging.

Community bank executives understand their loan books and local markets better than outside observers.

When several of them buy after a 50% decline, the signal deserves respect.

Amrize (AMRZ)

Amrize is a North American building-products company created through the separation of Holcim’s North American operations.

It sells cement, aggregates, ready-mix concrete, asphalt, roofing systems, and other construction products.

Shares have slid about 35% from a high of $65.94 to approximately $43, near the low end of the stock’s trading range.

Investors are worried about construction demand, interest rates, and the usual uncertainty that follows a spinoff.

The C-suite appears to see opportunity.

In August, CFO Oran Baris bought 6,000 shares for approximately $284,000.

The chief technology officer, chief supply chain officer, chief people officer, and chief strategy and mergers officer also purchased shares.

Chairman and CEO Jan Jenisch had already purchased more than 47,000 shares in May for approximately $2.35 million.

This is not one lonely director buying a few hundred shares.

It is broad participation from the executives responsible for finance, operations, technology, strategy, and supply chains.

Amrize’s second-quarter results hardly resemble those of a collapsing business.

Revenue increased 8.6% to $3.49 billion.

Organic growth was 6.7%, net income increased 14.4% to $476 million, and adjusted EBITDA reached $986 million.

Management raised full-year revenue guidance to between $12.5 billion and $12.7 billion and expects adjusted EBITDA of $3.1 billion to $3.2 billion.

The market sees a cyclical building-products company facing an uncertain environment.

Management appears to see a durable collection of hard assets, strong regional positions, and significant cash-generating power.

At the current price, I find management’s interpretation increasingly persuasive.

Follow the Money

None of these purchases makes the stocks risk-free.

Boston Scientific must deal with operational disruptions and acquisition execution.

Cardinal has to translate explosive growth into dependable margins.

GBank must maintain credit quality.

Amrize remains exposed to construction cycles and interest rates.

Those risks help explain why the opportunities exist.

The best insider-buying setups rarely appear when everything is perfect.

They occur when the stock has been crushed, the headlines are ugly, and investors have stopped giving management the benefit of the doubt.

That is exactly when I want to know what insiders are doing.

I do not want executives telling me the stock is undervalued during a conference call.

Every executive says that.

I want to see them file a Form 4 showing they bought shares with their own money.

Boston Scientific, Cardinal Infrastructure, GBank Financial, and Amrize all have executives doing exactly that.

In some cases, we are talking about millions of dollars.

In others, multiple members of the management team are buying at the same time.

The combined message is simple.

Wall Street sees falling knives.

The people closest to these businesses see prices worth buying.

They may be early.

Deep-value investors often are.

They may even be wrong.

But when executives with far more information about the underlying business than the average investor start committing serious amounts of their own money after a major decline, I want to investigate.

If their assessment of the underlying businesses is correct, these depressed prices could look remarkably attractive a few years from today.